1. Podolsky DK. Inflammatory bowel disease. N Engl J Med. 2002. 347:417–429.
Article
6. Peeters M, Joossens S, Vermeire S, Vlietinck R, Bossuyt X, Rutgeerts P. Diagnostic value of anti-Saccharomyces cerevisiae and antineutrophil cytoplasmic autoantibodies in inflammatory bowel disease. Am J Gastroenterol. 2001. 96:730–734.
Article
7. Chutkan RK, Scherl E, Waye JD. Colonoscopy in inflammatory bowel disease. Gastrointest Endosc Clin N Am. 2002. 12:463–483.
Article
9. Cohen R, Woseth DM, Thisted RA, Hanauer SB. A Meta-analysis and overview of the literature on treatment options for left-sided ulcerative colitis and ulcerative proctitis. Am J Gastroenterol. 2000. 95:1263–1276.
Article
10. Sandborn WJ. Rational selection of oral 5-aminosalicylate formulations and prodrugs for the treatment of ulcerative colitis. Am J Gastroenterol. 2002. 97:2939–2941.
Article
12. Faubion WA Jr, Loftus EV Jr, Harmsen WS, Zinsmeister AR, Sandborn WJ. The natural history of corticosteroid therapy for inflammatory bowel disease : a population-based study. Gastroenterology. 2001. 121:255–260.
Article
13. Danielsson A, Lofberg R, Persson T. A steroid enema, budesonide, lacking systemic effects for the treatment of distal ulcerative colitis or proctitis. Scand J Gastroenterol. 1992. 27:9–12.
Article
14. Greenberg GR, Feagan BG, Martin F, Sutherland LR, Thomson AB, Persson T, et al. Canadian Inflammatory Bowel Disease Study Group. Oral budesonide as maintenance treatment for Crohn's disease : a placebo-controlled, dose-ranging study. Gastroenterology. 1996. 110:45–51.
Article
17. Fraser AG, Orchard TR, Jewel DP. The efficacy of azathioprine for the treatment of inflammatory bowel disease. Gut. 2002. 50:485–489.
Article
18. Present DH, Melzer SJ, Krumholz MP, Wolke A, Korelitz BI. 6-Mercaptopurine in the management of inflammatory bowel disease : short and long-term toxicity. Ann Intern Med. 1989. 111:641–649.
Article
19. Seidman EG. 6-Mercaptopurine in maintaining remission in Crohns disease : An old friend becomes a new hero. Gastroenterology. 2000. 119:1158–1160.
Article
21. van Dullemen HM, van Deventer SJ, Hommes DW, Bijl HA, Jansen J, Woody J, et al. Treatment of Crohn's disease with anti-tumor necrosis factor chimeric monoclonal antibody (cA2). Gastroenterology. 1995. 109:129–135.
Article
22. Targan SR, Hanauer SB, van Deventer SJ, Mayer L, Present DH, Rutgeerts PJ, et al. Crohn's Disease cA2 Study Group. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. N Engl J Med. 1997. 337:1029–1023.
Article
23. Present DH, Rutgeerts P, Targan S, Hanauer SB, Mayer L, van Deventer SJ, et al. Infliximab for the treatment of fistulas in patients with Crohn's disease. N Engl J Med. 1999. 340:1398–1405.
Article
24. Sutherland L, Singleton J, Sessions J, Hanauer S, Krawitt E, Kelly M, et al. Double blind, placebo controlled trial of metronidazole in Crohn's disease. Gut. 1991. 32:1071–1075.
Article
25. Turunen UM, Farkkila MA, Hakala K, Seppala K, Sivonen A, Miettinen TA. Long-term treatment of ulcerative colitis with ciprofloxacin : a prospective, double-blind, placebo-controlled study. Gastroenterology. 1998. 115:1072–1078.
Article
26. Gionchetti P, Rizzello F, Venturi A, Brigidi P, Matteuzzi D, Campieri M. Oral bacteriotherapy as maintenance treatment in patients with chronic pouchitis : a double-blind, placebo-controlled trial. Gastroenterology. 2000. 119:305–309.
Article